B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern.
G.A. Pangalis(University of West Attica), Christos Kittas(National and Kapodistrian University of Athens), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
PubMed
January 1, 1988
Cited by 24
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859